This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Delving into the POLARIX trial data on Roche's Polivy in patients with Diffuse Large B Cell Lymphoma (DLBCL).

Ticker(s): RHHBY

Who's the expert?

Institution: Virginia Mason Medical Center

  • Staff Hematologist and Oncologist at Virginia Mason Medical Center.
  • Currently manages 10 patients with Diffuse Large B Cell Lymphoma (DLBCL).
  • Expertise in malignant hematology and genitourinary oncology with interests in coagulation disorders.

Interview Goal
to discuss the standard of care and the potential of Roche/Genentech's antibody-drug conjugate Polivy (polatuzumab vedotin-piiq), combined with the cancer regimen R-CHP, which was recently approved for the additional indication of first-line DLBCL.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.